Cancer charity Myeloma UK and biotechnolgy firm Oncolytics Biotech have commenced a Phase Ib MUK eleven trial of Reolysin (pelareorep) in combination with Imnovid (pomalidomide) or Revlimid (lenalidomide) to treat patients with relapsing myeloma.

Reolysin is Oncolytics' proprietary variant of the respiratory enteric orphan virus (reovirus), while Imnovid and Revlimid are Celgene's immunomodulatory drugs (IMiDs).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The dose escalation Phase Ib trial will evaluate the safety and tolerability of the combinations in patients whose myeloma is progressing while on these IMiD treatments.

Oncolytics president and chief executive officer Dr Matt Coffey said: "This is an important collaboration for Oncolytics, as testing IMiD combinations with Reolysin is one of the three pillars of our clinical development plan.

"This is an important collaboration for Oncolytics, as testing IMiD combinations with Reolysin is one of the three pillars of our clinical development plan."

"We are eager to find out if Reolysin can enhance the benefits of these immune modulators and we are excited to start working with Myeloma UK and Celgene."

Pre-clinical studies by the trial's chief investigator Gordon Cook showed that Reolysin has dual modes of action against multiple myeloma, as it is both cytotoxic and induces immune effector cells to target and kill cancer cells.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Cook said: "This trial, the first of its kind, is a novel way of activating a patient's own immune system to target their myeloma (immunotherapy) using a natural virus and lenalidomide or pomalidomide, which could offer a new treatment strategy in myeloma."

A part of the Myeloma UK clinical trial network, the MUK eleven trial will enrol 44 patients across approximately six centres in the country.

The trial will also assess the ability of Reolysin to extend disease control in this patient group.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact